Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented positive Phase 2 data for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The data were shared in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The...

NEW YORK--(BUSINESS WIRE)--Metropolitan Commercial Bank (“MCB” or the “Bank”), a full-service commercial bank headquartered in New York City, is proud to announce that it has been Certified™ by Great Place To Work® for the second year in a row, reaffirming the Bank's commitment to fostering an exceptional workplace culture where employees feel valued, supported, and empowered to succeed. Great Place To Work® is the global authority on workplace culture, employee experience, and the leadership b...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (“Genius Sports”) (NYSE:GENI) today announced that it will release its third quarter 2026 results before 8:00AM ET on Thursday, November 5, 2026. At 8:00AM ET on the same day, Genius Sports will host a conference call to discuss the results. Genius Sports’ earnings press release and related materials will be available at investors.geniussports.com. To listen to the live audio webcast and Q&A, please visit Genius Sports’ investor rela...

SAN DIEGO--(BUSINESS WIRE)--Jack in the Box Inc. (NASDAQ: JACK) today announced that it will report fourth quarter and full-year fiscal 2026 financial results after market close on Wednesday, December 9, 2026. The Company will host a conference call and webcast to discuss the results at 5:00 p.m. ET that same day. The live webcast will be available on the Jack in the Box investor relations website at investors.jackinthebox.com, where a replay will also be available following the event. The timi...

BOSTON--(BUSINESS WIRE)--RyCarma Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class small molecule therapeutics for skeletal muscle diseases, today announced that the first patient was dosed in a Phase 2 clinical trial of surlorian in patients with RYR1-related myopathy (RYR1-RM). RYR1-RM is caused by a mutation in the RYR1 gene and is one of the most prevalent congenital skeletal muscle disorders. The disease is characterized by impaired muscle contraction, we...